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Coronary heart disease (CHD) is one of the 
leading causes of disability and death worldwide, 
which includes angina pectoris, myocardial infarc-
tion, as well as arterial sclerosis of the coronary 
arteries [1]. It is widely accepted that CHD is 
a multifactorial disease. Several factors (hereditary, 
social-environmental factors, and their interac-
tions) contribute to the onset of CHD.
The interleukin-6 (IL-6) gene locates on 7p21. 
Previous epidemiological studies revealed that 
plasma levels of IL-6 in people with cardiovascu-
lar disease (CVD) are quite different from those 
without CVD [2, 3]. Till now, many studies have 
investigated the association between IL-6 gene 
-572G>C polymorphism and CHD risk. However, 
the results are inconsistent. In order to avoid 
the limitations of single case-control study and 
to provide renewed evidence, we performed this 
meta-analysis and tried to give a more comprehen-
sive estimation of association between IL-6 gene 
-572G>C polymorphism and CHD susceptibility.
We searched in PubMed, EMBASE, EBSCO, 
and Chinese National Knowledge Infrastructure 
(CNKI) to retrieve relevant studies until May 1, 
2016. Studies were considered eligible if they met 
the following criteria: (1) it was a case-control 
study in design; (2) it evaluated the IL-6 gene 
-572G>C polymorphism and CHD susceptibility; 
(3) the diagnosis of CHD was definite; (4) sample 
sizes and individual genotype frequencies were 
available. Two reviewers independently searched 
and selected literature, and extracted relevant 
data according to a data extraction form. Disagree-
ments were solved by discussion until consensus 
was made.
For each included study, the quality assessment 
was conducted according to STREGA (STrengthen-
ing the REporting of Genetic Association studies). 
Data analysis was conducted using STATA 11.0 
software (Stata Statistical software, USA, www.
stata.com). Odds ratio (OR) and its corresponding 
95% confidence intervals (95% CI) were used to 
evaluate the strength of association. Heterogeneity 
among included studies was tested using c2-based 
Q test and I2 test. The Mantel-Haenszel method 
was used for fix-effect model if no heterogeneity 
was found. Otherwise, the DerSimonian-Laird 
random-effect model was used. Five comparisons 
of genetic models were conduced, including the 
dominant model (GG+GC vs. CC), the recessive 
model (GG vs. GC+CC), the allele contrast genetic 
model (G vs. C), the heterozygote comparison (GC 
vs. CC), and the homozygote comparison (GG 
vs. CC). Sensitivity analyses were conducted by 
omitting individual studies sequentially. Publica-
tion bias was quantitatively assessed by Begg’s 
rank correlation test. Subgroup analyses strati-
fied by ethnicity, source of control and deviation 
from Hardy-Weinberg equilibrium (HWE) were 
conducted. Meta-regression test was used for the 
assessment of heterogeneity, characteristics tested 
included ethnicity, source of control, deviation from 
HWE, and sample size. P < 0.05 showed statistical 
significance.
Finally, 19 case-control studies including 4,545 
cases and 7,720 controls were included in this 
meta-analysis. Table 1 presents the main charac-
teristics, genotype frequencies of included studies, 
deviation from HWE in control groups, and quality 
of each study. The combined results based on all 
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studies showed that a significant increase of CHD 
susceptibility was found in the dominant model 
(GG+GC vs. CC: OR = 1.044, 95% CI 1.006–1.084, 
p = 0.023), the heterozygote comparison (GC vs. 
CC: OR = 1.086, 95% CI 1.012–1.166, p = 0.021), 
and the allele contrast genetic model (G vs. C: 
OR = 1.046, 95% CI 1.007–1.086, p = 0.021), 
but not in the recessive model (GG vs. GC+CC: 
OR = 1.007, 95% CI 0.959–1.058, p = 0.770), or the 
homozygote comparison (GG vs. CC: OR = 1.009, 
95% CI 0.980–1.039, p = 0.544). In the subgroup 
analysis stratified by ethnicity, significant increase 
of CHD susceptibility was found in Asians in the 
dominant model (GG+GC vs. CC: OR = 1.168, 
95% CI 1.040–1.312, p = 0.009) and the allele 
contrast genetic model (C vs. G: OR = 1.223, 95% 
CI 1.078–1.387, p = 0.002). The detailed outcomes 
of subgroup analyses are shown in Table 2. Figure 1 
Table 2. Results of subgroup analyses of IL-6 gene -572G>C polymorphism.
Stratified by Comparison Number of 
datasets
Dominant genetic model Allele contrast
OR (95% CI) P OR (95% CI) P
Ethnicity Asian 13 1.168 (1.040–1.312) 0.009 1.223 (1.078–1.387) 0.002
Caucasian 6 1.004 (0.994–1.015) 0.426 1.001 (0.990–1.012) 0.864
Source of control PB 14 1.052 (1.007–1.098) 0.023 1.046 (1.003–1.091) 0.034
HB 5 1.044 (0.944–1.155) 0.405 1.059 (0.947–1.185) 0.313
Deviation from HWE Yes 3 1.127 (0.936–1.358) 0.207 1.167 (0.950–1.434) 1.47
No 16 1.031 (0.994–1.069) 0.099 1.029 (0.992–1.067) 1.52
CI — confidence interval; HB — hospital-based study; HWE — Hardy-Weinberg equilibrium; OR — odds ratio; PB — population-based study
Figure 1. The association between IL-6 gene -572G>C polymorphism and coronary heart disease susceptibility in the 
allele contrast genetic model stratified by ethnicity; CI — confidence interval; OR — odds ratio.
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shows the association between IL-6 gene -572G>C 
polymorphism and CHD susceptibility in the allele 
contrast genetic model stratified by ethnicity.
Through Begg’s rank correlation test, we 
identified heterogeneity in the dominant model, 
the allele contrast genetic model, and the ho-
mozygote comparison, but not for the other two 
genetic models. In the sensitivity analyses, the 
result did not change under any genetic model, 
which suggested that the results of main analysis 
were statistically robust. In meta-regression, the 
univariate regression test showed that ethnicity 
(I2-residual = 40.1%, adj-R2 = 41.8%, p = 0.04) 
were the significant source of heterogeneity among 
studies.
Cytokine genes have been supposed to be 
of crucial role in diseases susceptibility and host 
genetic polymorphisms. IL-6 has a broad range of 
cellular and humoral properties in relation to the 
etiology and inflammatory response of CHD [4, 5]. 
Previous studies have demonstrated that plasma 
levels of IL-6 may be associated with CHD risk and 
that the -572G allele was associated with lower se-
rum level of IL-6 concentrations compared with the 
-572C allele [6, 7]. Therefore, it is quite reasonable 
to deduce that IL-6 gene -572G>C polymorphism 
is associated with CHD susceptibility.
Comparing with two previous meta-analy-
ses focusing on association between IL-6 gene 
-572G>C polymorphism [8, 9], our study has 
some important improvements. Firstly, some new 
studies were published and they were included 
in our meta-analysis. Moreover, in the present 
study, we conducted subgroup analyses and meta-
regression test to identify the potential source of 
heterogeneity. Through subgroup analyses, we 
found that G allele of -572G>C polymorphism 
was significantly associated with increased CHD 
susceptibility in Asians, but the effect size was 
weak. Meta-regression test showed that ethnicity 
(I2-residual = 40.1%, adj-R2 = 41.8%, p = 0.04) 
was a significant source of heterogeneity among 
the studies. Therefore, the different ethnicity 
contributed to the overall heterogeneity. We also 
have to note the limitations of this study. Firstly, 
we only included published studies meeting our 
inclusion criteria from four databases, similar stud-
ies in other databases and unpublished researches 
may have been missed. Moreover, the possible 
pathogenesis of CHD is comprehensive, but due to 
insufficiency of included studies, we did not detect 
the interactions between genetic factors and other 
environmental or lifestyle factors.
In conclusion, from the combined results 
of currently included studies, our meta-analysis 
suggests that the G allele of IL-6 gene -572G>C 
polymorphism is significantly associated with 
increased CHD susceptibility in Asians, but the 
effect size is weak. More studies with multiple 
ethnicities and different genders are needed to 
generalize the results.
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